SCHEMBL5228271

SCHEMBL5228271

CCOc1cc(N2CCN(C)CC2)ccc1-c1nc2c(c(-c3ccccc3)nn2C)c(=O)[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 14/20 0.55
PDE7A Q13946 2/20 0.55
KHK P50053 1/20 0.44
PDE1A P54750 1/20 0.43
PDE1B Q01064 1/20 0.43
PDE1C Q14123 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
MEN1 O00255 1/20 0.42
SLCO2B1 O94956 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
BCL2L1 Q07817 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLCO1B3 Q9NPD5 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233490 0.91 PDE7A (0.47) PDE5APDE7AADORA2AADORA1MEN1
SCHEMBL5230869 0.89 PDE5A (0.50) PDE5APDE7APDE1APDE1BPDE1C
SCHEMBL5236578 0.88 PDE5A (0.44) PDE5APDE7AADORA2AADORA1ALDH1A1
SCHEMBL5233730 0.85 PDE5A (0.59) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL5228663 0.85 PDE7A (0.45) PDE5APDE7AMEN1ALDH1A1MAPT
SCHEMBL5231543 0.85 PDE7A (0.46) PDE5APDE7AADORA2AADORA1MEN1
SCHEMBL5228467 0.85 PDE7A (0.46) PDE5APDE7AMEN1KMT2A
SCHEMBL5231446 0.83 PDE7A (0.53) PDE5APDE7AKHK
SCHEMBL5234605 0.83 PDE7A (0.47) PDE5APDE7AMEN1ALDH1A1MAPT
SCHEMBL5228627 0.83 PDE7A (0.48) PDE5APDE7AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE5A 8/4885PDE7A 4/4885KHK 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.